Souhaitez-vous accéder aux communiqués récents ?

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent...

Austin, United States, May 28, 2026 (GLOBE NEWSWIRE) -- “The Drug Discovery Market was valued at USD 71.95 billion in 2025 and is projected to surpass USD 174.92 billion by 2035, growing at a CAGR...

Fortis Life Sciences launches AbNano® VHH Anti-NK Cell Library, the first NK-cell-derived single-domain antibody library for rapid discovery.

The Logical Qubit Pathway Strategy Intends to Integrate the Company’s’ Error Correction Transformer to Reach Modular Infrastructure Tel Aviv, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Quantum X...

Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics

Dublin, May 25, 2026 (GLOBE NEWSWIRE) -- The "Biosimulation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering....

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Advanced Pharmacovigilance Auditing and Inspections (Sept 3rd - Sept 4th, 2026)" training has been added to ResearchAndMarkets.com's offering. This...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...

Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "The FDA Drug Approval Process (Sept 24th - Sept 25th, 2026)" training has been added to ResearchAndMarkets.com's offering. The US is the largest...